175 related articles for article (PubMed ID: 25450772)
1. Farnesyltransferase and geranylgeranyltransferase I: structures, mechanism, inhibitors and molecular modeling.
Shen M; Pan P; Li Y; Li D; Yu H; Hou T
Drug Discov Today; 2015 Feb; 20(2):267-76. PubMed ID: 25450772
[TBL] [Abstract][Full Text] [Related]
2. Theoretical studies on binding and specificity mechanisms of farnesyltransferase (FTase) and geranylgeranyltransferase type-I (GGTase-I) inhibitors by molecular modeling.
Zhou S
Comb Chem High Throughput Screen; 2014; 17(6):509-19. PubMed ID: 24444014
[TBL] [Abstract][Full Text] [Related]
3. Conversion of protein farnesyltransferase to a geranylgeranyltransferase.
Terry KL; Casey PJ; Beese LS
Biochemistry; 2006 Aug; 45(32):9746-55. PubMed ID: 16893176
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, and characterization of piperazinedione-based dual protein inhibitors for both farnesyltransferase and geranylgeranyltransferase-I.
Qiao Y; Gao J; Qiu Y; Wu L; Guo F; Lo KK; Li D
Eur J Med Chem; 2011 Jun; 46(6):2264-73. PubMed ID: 21440964
[TBL] [Abstract][Full Text] [Related]
5. Inactivation of farnesyltransferase and geranylgeranyltransferase I by caspase-3: cleavage of the common alpha subunit during apoptosis.
Kim KW; Chung HH; Chung CW; Kim IK; Miura M; Wang S; Zhu H; Moon KD; Rha GB; Park JH; Jo DG; Woo HN; Song YH; Kim BJ; Yuan J; Jung YK
Oncogene; 2001 Jan; 20(3):358-66. PubMed ID: 11313965
[TBL] [Abstract][Full Text] [Related]
6. Crystallographic analysis reveals that anticancer clinical candidate L-778,123 inhibits protein farnesyltransferase and geranylgeranyltransferase-I by different binding modes.
Reid TS; Long SB; Beese LS
Biochemistry; 2004 Jul; 43(28):9000-8. PubMed ID: 15248757
[TBL] [Abstract][Full Text] [Related]
7. Genetic evidence for in vivo cross-specificity of the CaaX-box protein prenyltransferases farnesyltransferase and geranylgeranyltransferase-I in Saccharomyces cerevisiae.
Trueblood CE; Ohya Y; Rine J
Mol Cell Biol; 1993 Jul; 13(7):4260-75. PubMed ID: 8321228
[TBL] [Abstract][Full Text] [Related]
8. Crystallographic analysis of CaaX prenyltransferases complexed with substrates defines rules of protein substrate selectivity.
Reid TS; Terry KL; Casey PJ; Beese LS
J Mol Biol; 2004 Oct; 343(2):417-33. PubMed ID: 15451670
[TBL] [Abstract][Full Text] [Related]
9. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies.
Sebti SM; Hamilton AD
Oncogene; 2000 Dec; 19(56):6584-93. PubMed ID: 11426643
[TBL] [Abstract][Full Text] [Related]
10. Farnesyltransferase inhibitors: a detailed chemical view on an elusive biological problem.
Sousa SF; Fernandes PA; Ramos MJ
Curr Med Chem; 2008; 15(15):1478-92. PubMed ID: 18537624
[TBL] [Abstract][Full Text] [Related]
11. Crystal structures of the anticancer clinical candidates R115777 (Tipifarnib) and BMS-214662 complexed with protein farnesyltransferase suggest a mechanism of FTI selectivity.
Reid TS; Beese LS
Biochemistry; 2004 Jun; 43(22):6877-84. PubMed ID: 15170324
[TBL] [Abstract][Full Text] [Related]
12. Amino acid residues that define both the isoprenoid and CAAX preferences of the Saccharomyces cerevisiae protein farnesyltransferase. Creating the perfect farnesyltransferase.
Caplin BE; Ohya Y; Marshall MS
J Biol Chem; 1998 Apr; 273(16):9472-9. PubMed ID: 9545274
[TBL] [Abstract][Full Text] [Related]
13. Targeted reengineering of protein geranylgeranyltransferase type I selectivity functionally implicates active-site residues in protein-substrate recognition.
Gangopadhyay SA; Losito EL; Hougland JL
Biochemistry; 2014 Jan; 53(2):434-46. PubMed ID: 24344934
[TBL] [Abstract][Full Text] [Related]
14. Reaction path of protein farnesyltransferase at atomic resolution.
Long SB; Casey PJ; Beese LS
Nature; 2002 Oct; 419(6907):645-50. PubMed ID: 12374986
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, and biological activity of 4-[(4-cyano-2-arylbenzyloxy)-(3-methyl-3H-imidazol-4-yl)methyl]benzonitriles as potent and selective farnesyltransferase inhibitors.
Wang L; Wang GT; Wang X; Tong Y; Sullivan G; Park D; Leonard NM; Li Q; Cohen J; Gu WZ; Zhang H; Bauch JL; Jakob CG; Hutchins CW; Stoll VS; Marsh K; Rosenberg SH; Sham HL; Lin NH
J Med Chem; 2004 Jan; 47(3):612-26. PubMed ID: 14736242
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines.
Lerner EC; Zhang TT; Knowles DB; Qian Y; Hamilton AD; Sebti SM
Oncogene; 1997 Sep; 15(11):1283-8. PubMed ID: 9315095
[TBL] [Abstract][Full Text] [Related]
17. [Inhibitors of isoprenylation of ras p21].
Yoshimatsu K
Gan To Kagaku Ryoho; 1997 Sep; 24(11):1495-502. PubMed ID: 9309147
[TBL] [Abstract][Full Text] [Related]
18. Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts.
Sun J; Qian Y; Hamilton AD; Sebti SM
Oncogene; 1998 Mar; 16(11):1467-73. PubMed ID: 9525745
[TBL] [Abstract][Full Text] [Related]
19. Farnesyltransferase and geranylgeranyltransferase I inhibitors in cancer therapy: important mechanistic and bench to bedside issues.
Sebti SM; Hamilton AD
Expert Opin Investig Drugs; 2000 Dec; 9(12):2767-82. PubMed ID: 11093352
[TBL] [Abstract][Full Text] [Related]
20. A mutant form of human protein farnesyltransferase exhibits increased resistance to farnesyltransferase inhibitors.
Del Villar K; Urano J; Guo L; Tamanoi F
J Biol Chem; 1999 Sep; 274(38):27010-7. PubMed ID: 10480914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
